Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Neos Therapeutics, Inc is a drug manufacturers—specialty & generic business based in the US. Neos Therapeutics shares (NEOS) are listed on the NASDAQ and all prices are listed in US Dollars. Neos Therapeutics employs 213 staff and has a trailing 12-month revenue of around USD$57 million.
|Latest market close||USD$0.553|
|52-week range||USD$0.45 - USD$1.98|
|50-day moving average||USD$0.6142|
|200-day moving average||USD$0.6748|
|Wall St. target price||USD$5.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.783|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-24.25%|
|1 month (2020-12-16)||-18.32%|
|3 months (2020-10-15)||16.42%|
|6 months (2020-07-15)||-12.91%|
|1 year (2020-01-15)||-64.09%|
|2 years (2019-01-15)||-76.06%|
|3 years (2018-01-12)||10.375|
|5 years (2016-01-15)||9.68|
|Revenue TTM||USD$57 million|
|Gross profit TTM||USD$39.5 million|
|Return on assets TTM||-10.71%|
|Return on equity TTM||0%|
|Market capitalisation||USD$29.9 million|
TTM: trailing 12 months
There are currently 2.1 million Neos Therapeutics shares held short by investors – that's known as Neos Therapeutics's "short interest". This figure is 1.8% down from 2.1 million last month.
There are a few different ways that this level of interest in shorting Neos Therapeutics shares can be evaluated.
Neos Therapeutics's "short interest ratio" (SIR) is the quantity of Neos Therapeutics shares currently shorted divided by the average quantity of Neos Therapeutics shares traded daily (recently around 1.6 million). Neos Therapeutics's SIR currently stands at 1.3. In other words for every 100,000 Neos Therapeutics shares traded daily on the market, roughly 1300 shares are currently held short.
However Neos Therapeutics's short interest can also be evaluated against the total number of Neos Therapeutics shares, or, against the total number of tradable Neos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neos Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Neos Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0425% of the tradable shares (for every 100,000 tradable Neos Therapeutics shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neos Therapeutics.
Find out more about how you can short Neos Therapeutics stock.
We're not expecting Neos Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Neos Therapeutics's shares have ranged in value from as little as $0.45 up to $1.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neos Therapeutics's is 1.7294. This would suggest that Neos Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.